175 related articles for article (PubMed ID: 17057790)
1. Intravitreal clearance of moxifloxacin.
Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER
Trans Am Ophthalmol Soc; 2005; 103():76-81; discussion 81-3. PubMed ID: 17057790
[TBL] [Abstract][Full Text] [Related]
2. Clearance of intravitreal moxifloxacin.
Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):317-9. PubMed ID: 16384979
[TBL] [Abstract][Full Text] [Related]
3. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
4. Clearance of intravitreal voriconazole.
Shen YC; Wang MY; Wang CY; Tsai TC; Tsai HY; Lee YF; Wei LC
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2238-41. PubMed ID: 17460285
[TBL] [Abstract][Full Text] [Related]
5. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
6. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP
Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.
Ermis SS; Cetinkaya Z; Kiyici H; Inan UU; Ozturk F
Curr Eye Res; 2007 Apr; 32(4):337-44. PubMed ID: 17453955
[TBL] [Abstract][Full Text] [Related]
8. Vitreal penetration of oral moxifloxacin in humans.
Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
[TBL] [Abstract][Full Text] [Related]
9. The effect of cataract surgery on ocular levels of topical moxifloxacin.
Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD
Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780
[TBL] [Abstract][Full Text] [Related]
10. Vitreous and aqueous penetration of orally and topically administered moxifloxacin.
Fukuda M; Shibata N; Osada H; Yamashiro Y; Sasaki H
Ophthalmic Res; 2011; 46(3):113-7. PubMed ID: 21325873
[TBL] [Abstract][Full Text] [Related]
11. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
Asena L; Akova YA; Goktaş MT; Bozkurt A; Yaşar U; Karabay G; Demiralay E
Curr Eye Res; 2013 Apr; 38(4):472-9. PubMed ID: 23373761
[TBL] [Abstract][Full Text] [Related]
12. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing.
Levine JM; Noecker RJ; Lane LC; Herrygers L; Nix D; Snyder RW
J Cataract Refract Surg; 2004 Oct; 30(10):2177-82. PubMed ID: 15474833
[TBL] [Abstract][Full Text] [Related]
13. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
[TBL] [Abstract][Full Text] [Related]
15. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery.
Ong-Tone L
J Cataract Refract Surg; 2008 May; 34(5):819-22. PubMed ID: 18471639
[TBL] [Abstract][Full Text] [Related]
16. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
Hariprasad SM; Blinder KJ; Shah GK; Apte RS; Rosenblatt B; Holekamp NM; Thomas MA; Mieler WF; Chi J; Prince RA
Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810
[TBL] [Abstract][Full Text] [Related]
17. Vitreal penetration of oral and topical moxifloxacin in humans.
Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525
[TBL] [Abstract][Full Text] [Related]
18. Disposition kinetics of moxifloxacin in lactating ewes.
Goudah A
Vet J; 2008 Nov; 178(2):282-7. PubMed ID: 17900948
[TBL] [Abstract][Full Text] [Related]
19. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA
Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
[TBL] [Abstract][Full Text] [Related]
20. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
